OUR GOAL IS TO BE A LEADER IN THE DEVELOPEMENT OF TARGETED THERAPIES FOR PATIENTS WITH CANCER AND OTHER DISEASES OF HIGH UNMET NEED
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway, and is being studied in a pivotal Phase 3 and multiple Phase 2 trials. Our other product candidates are TRC102, a small molecule that is in Phase 2 clinical development for the treatment of mesothelioma and glioblastoma; TRC253, an small molecule inhibitor of wild type and mutated forms of the androgen receptor that is in Phase 2 clinical development for prostate cancer, TRC694 a small molecule inhibitor of NF-kB inducing kinase (NIK), that is in preclinical development for hematologic malignancies; and TRC205, an endoglin antibody that is in preclinical development for the treatment of fibrotic diseases. In 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our endoglin antibodies for ophthalmology indications, including AMD, and Santen is currently sponsoring a Phase 2 trial in wet AMD. In 2017 we licensed TRC105 commercial rights in greater China outside of ophthalmology to Ambrx. We retain rights to develop and commercialize our endoglin antibodies outside of the field of ophthalmology in the US and Europe. The TRC253 and TRC694 product candidates are being developed in collaboration with Janssen Pharmaceutica N.V.
We operate a clinical development model that emphasizes capital efficiency. Our experienced clinical operations, product development and regulatory affairs groups enable us to eliminate the cost associated with hiring contract research organizations to manage clinical, regulatory and database aspects of our Phase 1, Phase 2 and Phase 3 clinical trials. We have also collaborated with the National Cancer Institute, which selected TRC105 and TRC102 for federal funding of clinical development, as well as Case Western Reserve University. Under these collaborations, NCI has sponsored or is sponsoring seven completed or ongoing clinical trials of TRC105 and TRC102, and Case Western is sponsoring two ongoing clinical trials of TRC102.